Skip to main content

Table 3 Prevalence, sensitivity, specificity and OR of numbers of RF isotypes, alone and in combination with the three most frequent ACPA specificities, anti-CCP2 antibodies and anti-carbamylated protein antibodies in pre-symptomatic individuals and population control subjects

From: Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis

Antibody/combination Pre-symptomatic (n) Control subjects (n) Sensitivity % (95 % CI) Specificity % (95 % CI) OR (95 % CI)
1 RF 123 39 20.6 (17.5–24) 92.1 (89.3–94.2) 3 (2.1–4.4)
2 RF 56 7 9.4 (7.3–12) 98.6 (97–99.4) 7.2 (3.2–15.9)
3 RF 58 1 9.7 (7.6–12.4) 99.8 (98.7–100) 52.7 (7.3–382.2)
≥1 RF 237 47 39.6 (35.8–43.6) 90.4 (87.5–92.7) 6.2 (4.4–8.8)
≥2 RF 114 8 19.1 (16.1–22.4) 98.4 (96.7–99.2) 14.2 (6.9–29.5)
3 RF 58 1 9.7 (7.6–12.4) 99.8 (98.7–100) 52.7 (7.3–382.2)
CCP2 + ≥1 RF 124 3 20.7 (17.7–24.2) 99.4 (98.1–99.9) 42.6 (13.5–135)
CCP2+ ≥2 RF 83 2 13.9 (11.3–16.9) 99.6 (98.4–100) 39.5 (9.7–161.4)
CCP2 + 3 RF 50 1 8.4 (6.4–10.9) 99.8 (98.7–100) 44.8 (6.2–325.5)
CCP2 + ≥1 RF + CarP 35 0 6.1 (4.4–8.4) 100 (99–100)
CCP2+ ≥2 RF+ CarP 30 0 5.1 (3.6–7.3) 100 (99–100)
CCP2 + 3 RF+ CarP 22 0 3.7 (2.5–5.6) 100 (99–100)
CEP-1 + ≥1 RF 96 6 16.3 (13.5–19.5) 98.8 (97.2–99.5) 15.5 (6.7–35.7)
CEP-1+ ≥2 RF 64 3 10.8 (8.6–13.6) 99.4 (98.1–99.9) 19.5 (6.1–62.5)
CEP-1+ 3 RF 38 1 6.4 (4.7–8.7) 99.8 (98.7–100) 33.2 (4.5–243.1)
CEP-1 + ≥1 RF + CarP 28 0 4.9 (3.4–7) 100 (99–100)
CEP-1+ ≥2 RF + CarP 25 0 4.3 (2.9–6.3) 100 (99–100)
CEP-1+ 3 RF + CarP 17 0 2.9 (1.8–4.7) 100 (99–100)
Fibβ36–52 + ≥1 RF 91 6 15.4 (12.7–18.6) 98.8 (97.2–99.5) 14.5 (6.3–33.5)
Fibβ36–52 + ≥2 RF 57 2 9.7 (7.5–12.3) 99.6 (98.4–100) 25.8 (6.3–106.1)
Fibβ36–52 + 3 RF 35 1 5.9 (4.3–8.2) 99.8 (98.7–100) 30.5 (4.2–223.2)
Fibβ36–52 + ≥1 RF + CarP 23 0 4 (2.7–6) 100 (99–100)
Fibβ36–52 + ≥2 RF + CarP 20 0 3.4 (2.2–5.3) 100 (99–100)
Fibβ36–52 + 3 RF + CarP 14 0 2.4 (1.4–4) 100 (99–100)
Filaggrin + ≥1 RF 85 3 14.4 (11.8–17.5) 99.4 (98.1–99.9) 27 (8.5–85.9)
Filaggrin + ≥2 RF 56 2 9.5 (7.4–12.2) 99.6 (98.4–100) 25.3 (6.1–104.1)
Filaggrin + 3 RF 34 1 5.8 (4.1–8) 99.8 (98.7–100) 29.5 (4–216.6)
Filaggrin + ≥1 RF + CarP 23 0 4 (2.7–6) 100 (99–100)
Filaggrin + ≥2 RF+ CarP 20 0 3.4 (2.2–5.3) 100 (99–100)
Filaggrin + 3 RF + CarP 14 0 2.4 (1.4–4) 100 (99–100)
CEP-1 + Fibβ36–52 + Filaggrin + ≥1 RF 37 1 6.3 (4.6–8.6) 99.8 (98.7–100) 32.3 (4.4–236.4)
CEP-1 + Fibβ36–52 + Filaggrin + ≥2 RF 28 1 4.7 (3.3–6.8) 99.8 (98.7–100) 24.1 (3.3–177.5)
CEP-1 + Fibβ36–52 + Filaggrin + 3 RF 20 1 3.4 (2.2–5.2) 99.8 (98.7–100) 16.9 (2.3–126.7)
CEP-1 + Fibβ36–52 + Filaggrin + ≥1 RF + CarP 13 0 2.2 (1.3–3.8) 100 (99–100)
CEP-1 + Fibβ36–52 + Filaggrin + ≥2 RF + CarP 12 0 2 (1.1–3.6) 100 (99–100)
CEP-1 + Fibβ36–52 + Filaggrin + 3 RF + CarP 10 0 1.7 (0.9–3.2) 100 (99–100)
  1. RF rheumatoid factor, CCP2 anti-CCP2 antibodies, Fibβ 36–52 Fibrinogenβ36–52, CEP-1 anti-α-enolase antibodies